"Aberrant expression of the enzymes that convert unsaturated fatty
acid arachidonic acid (AA) and linoleic acid (LA) to bioactive lipid
metabolites appears to significantly contribute to the development of
PCa. Many studies relating the development of cancer to lipid
metabolizing enzymes have focused on the increased expression of COX-2
in tumor tissue (2–,6). COX-2 is expressed in human prostate cancer
(4), but the lipoxygenase enzymes that convert unsaturated fatty acids
to hydroxylated metabolites also appear to play a role in prostate
cancer. For example, 12-LO (7,11–,15) promotes tumor cell adhesion and
endothelial cell transmigration, and may contribute to metastasis (12–,
14) and tumor growth via angiogenesis (15). In addition, Ghosh and
Myers (8,,16) reported selective 5-LO inhibitors but not 12-LO or COX
inhibitors suppress cell growth of PC-3 cells. Inhibitors of 5-LO and
5-LO-activating protein (FLAP) (17) can also induce apoptosis in PC-3
and LNCaP cell lines."
SOURCE:
http://carcin.oxfordjournals.org/content/22/11/1765.full